Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2951392
Reference Type
Journal Article
Title
Pharmacokinetic Evaluation Of Perfluorooctanoic Acid In The Mouse
Author(s)
Lau, C; Strynar, MJ; Lindstrom, AB; Hanson, RG; Thibodeaux, JR; Barton, HA
Year
2005
Is Peer Reviewed?
1
Journal
Toxicological Sciences
ISSN:
1096-6080
EISSN:
1096-0929
Report Number
TOX/5001366
Volume
84
Issue
1-S
Language
English
Abstract
Perfluorooctanoic acid (PFOA) is a stable chemical surfactant with wide industrial and consumer applications. Because PFOA has been detected in both human and wildlife populations, its potential adverse health effects are under active investigation. The pharmacokinetic properties of PFOA are unique: in the rat, there is a pronounced gender difference in its renal clearance such that half-life in females is estimated as 3 h and that in males as 5 days; however, such a major gender difference is absent in humans. The present study is designed to examine the pharmacokinetic properties of PFOA in another rodent species. Young male and female CD-1 mice received a single gavage administration of PFOA at either 1 or 10 mg/kg. Three animals from each group were sacrificed at 4 h, 8 h, 12 h, or 1, 3, 6, 9, 13, 20, 27, 34, 42, 48 days after treatment. Serum was prepared from trunk blood collected from the descending aorta and analyzed for PFOA by HPLC-MS-MS. PFOA was absorbed readily, reaching Cmax between 4-8 h. In contrast to the rat, no discernable sex difference in the disposition of PFOA was observed in the mouse. The terminal serum half-life of PFOA was estimated in the range of 15-20 days. A similar pharmacokinetic profile was seen in both dose groups, suggesting linearity between body burden of the fluorochemical and administered doses up to 10 mg/kg. These results thus indicate a significant difference in the pharmacokinetic disposition of PFOA between the rat and the mouse, with the profile of the latter species resembling the lack of an apparent sex-dependent elimination in humans.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity